DEVA:IST
Deva Holding AS
TRYÂ 75.30
arrow_downward
-2.08%(-1.60) 1D
Jul 22, 3:23:36 PM GMT+3 · TRY
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DEVA...
Open
TRYÂ 76.90
High
TRYÂ 77.35
Low
TRYÂ 74.95
Mkt. cap
15.06B
Avg. vol.
522.41K
Volume
698.20K
52-wk high
TRYÂ 81.75
52-wk low
TRYÂ 57.50
EPS
-TRYÂ 4.78
Shares outstanding
200.02M
No. of employees
3K
Open
TRYÂ 76.90
High
TRYÂ 77.35
Low
TRYÂ 74.95
Mkt. cap
15.06B
Avg. vol.
522.41K
Volume
698.20K
52-wk high
TRYÂ 81.75
52-wk low
TRYÂ 57.50
EPS
-TRYÂ 4.78
Shares outstanding
200.02M
No. of employees
3K
News stories
From sources across the web
Simply Wall Street
·
8 minutes ago
Galaxy Digital (NasdaqGS:GLXY) Launches Bitcoin Quantum Initiative And Anchors $130 Million Ripple Sale
Stock Titan
·
9 minutes ago
TON Plans Architecture Expected to Increase Transaction Capacity
Cadillac News
·
22 minutes ago
DataMEDS AI Officially Begins Trading Under Stock Symbol 'MEDS' on the NASDAQ Capital Markets
Yahoo Finance
·
4 hours ago
Stock market today: Dow, S&P 500, Nasdaq futures slide with Alphabet, Tesla earnings on deck
Profile
DEVA Holding A.Åž. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements.
A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas.
As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS
AI content may include mistakes. Learn more